Studies highlighting the protective roles of canonical gene targets of ATF6 have further fortified interest in pursuing ATF6-based therapeutics in clinically relevant disease models, namely AMI and pathological cardiac hypertrophy. The gene discussed is ATF6; the disease is cardiac hypertrophy.